An experienced partner to help navigate a complicated landscape.
Testing and proving neuroscience solutions can be challenging. With high placebo response rates, limited surrogate biomarkers and a host of patient recruitment and reporting difficulties, getting a drug or therapy approved is arduous. You need a trusted partner with dedicated neuroscience specialists and integrated services to stay on top of this ever-evolving field.
Therapeutic expertise for neuroscience.
- ALS
- Alzheimer's
- Parkinson's
- Epilepsy
- Multiple sclerosis
- Autism Spectrum Disorder
- ADHD
- Schizophrenia
- Chronic
- Acute
- Migraine
- Fragile X syndrome
- Mucopolysaccharidoses
- Muscular Dystrophies
- Batten disease
A fresh approach to neurodegenerative diseases.
We realize that our best chances of success lie in preventative measures established with the first early trial reproduced and expended in the next development stage. Fortrea utilizes its deep investigator network, comprehensive training tactics and innovative technology platform for risk management to gather quality data across geographies. We continually innovate in more empirical measures through wet, tissue, imaging and digital biomarkers to ease the burden on patients.
Effective, patient-centric strategies.
Understandably, within the entire field of neuroscience, psychiatric disorders are highly sensitive to risks that arise from non-compliance, controlled substance abuse and psychological instability. Fortrea’s clinical-studies experts have pioneered innovative approaches to recruit and retain these individuals, and possess the industry’s deepest knowledgebase to find investigators with the highest chances of success.
